Skip Navigation

European Journal of Heart Failure 2005 7(7):1085-1094; doi:10.1016/j.ejheart.2004.12.002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Westendorp, B.
Right arrow Articles by van Veldhuisen, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westendorp, B.
Right arrow Articles by van Veldhuisen, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril

Bart Westendorpa,*, Regien G. Schoemakera,b, Hendrik Buikemaa, Dick de Zeeuwa, Frans Boomsmac, Wiek H. van Gilsta,b and Dirk J. van Veldhuisenb

a Department of Clinical Pharmacology, University of Groningen A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
b Department of Cardiology, University Hospital Groningen The Netherlands
c Department of Internal Medicine, Erasmus University Medical Center Rotterdam, The Netherland

* Corresponding author. Tel.: +31 50 363 2724; fax: +31 50 363 2812. E-mail address: b.westendorp{at}med.rug.nl


  Abstract

Background: The antihypertensive and renoprotective effects of ACE inhibitor (ACEi) therapy are enhanced by inducing a negative sodium balance. Whether this strategy also improves outcome of chronic ACEi treatment after myocardial infarction (MI) is unknown. Therefore, we investigated whether hydrochlorothiazide (HCTZ) or dietary sodium restriction further improves survival in ACEi-treated rats with MI.

Methods: MI was induced by coronary ligation. After 2 weeks rats were randomised to quinapril (QUI), HCTZ added to quinapril (QUI+HCTZ), or low sodium diet added to quinapril (QUI+LS). Survival was monitored for 62 weeks, after which left ventricular (LV) pressures were measured and blood for neurohumoral characterisation was collected. A separate group of rats, subjected to the same procedure, was evaluated after 35 weeks.

Results: After 62 weeks, mortality was comparable in all groups. However, survival was improved by HCTZ until 35 weeks. This effect on survival was paralleled by decreased proteinuria and LV end-diastolic pressures in QUI+HCTZ rats at 35, but not 62 weeks. Plasma renin activity was significantly decreased in QUI+HCTZ rats at 35 weeks. Contrary to HCTZ, LS added to QUI caused no benefit.

Conclusions: Adding HCTZ, but not LS, to quinapril improved survival, neurohumoral status, and proteinuria during the early chronic phase of experimental post-MI LV dysfunction. Since no adverse effects were observed, HCTZ may safely be used to improve ACEi therapy.

Key Words: ACE inhibition • Experimental myocardial infarction • Rat • Diuretic • Renin angiotensin system

Received May 17, 2004; Revised October 29, 2004; Accepted December 9, 2004


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.